Advertisement

68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0

  • Wolfgang P. Fendler
  • Matthias Eiber
  • Mohsen Beheshti
  • Jamshed Bomanji
  • Francesco Ceci
  • Steven Cho
  • Frederik Giesel
  • Uwe Haberkorn
  • Thomas A. Hope
  • Klaus Kopka
  • Bernd J. Krause
  • Felix M. Mottaghy
  • Heiko Schöder
  • John Sunderland
  • Simon Wan
  • Hans-Jürgen Wester
  • Stefano Fanti
  • Ken HerrmannEmail author
Guidelines

Abstract

The aim of this guideline is to provide standards for the recommendation, performance, interpretation and reporting of 68Ga-PSMA PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of 68Ga-PSMA PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice.

Keywords

PSMA PET Prostate cancer Staging Restaging Guideline 

Notes

Acknowledgements

The authors thank the EANM and SNMMI committees and national delegates for their critical review of the manuscript. Also, we appreciate the great support of Sonja Niederkofler from the EANM office in Vienna, and Julie Kauffman from the SNMMI office in Reston during the development of this guideline.

Compliance with ethical standards

Conflict of interest

Matthias Eiber has a research grant from Siemens. Mohsen Beheshti is a member of the Oncology Committee of the EANM. Thomas Hope has research grants from GE Healthcare. Hans-Jürgen Wester is a shareholder of SCINTOMICS. Stefano Fanti is an advisory board member of BED, Bayer, and ANMI, receives travel support from Bayer, GE Healthcare, and Sanofi, and has grants from Movember and BED. All other authors declare no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

259_2017_3670_MOESM1_ESM.doc (90 kb)
ESM 1 (DOC 90 kb)

References

  1. 1.
    Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.PubMedGoogle Scholar
  2. 2.
    Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256–61.CrossRefPubMedGoogle Scholar
  3. 3.
    Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15:167–72.CrossRefPubMedGoogle Scholar
  4. 4.
    Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528–39.CrossRefPubMedGoogle Scholar
  5. 5.
    Ross JS, Sheehan CE, Fisher HA, Kaufman Jr RP, Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357–62.PubMedGoogle Scholar
  6. 6.
    Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53:5333–41.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97.CrossRefPubMedGoogle Scholar
  8. 8.
    Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95.CrossRefPubMedGoogle Scholar
  9. 9.
    Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The Theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705.CrossRefPubMedGoogle Scholar
  10. 10.
    Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56:855–61.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Busemann Sokole E, Plachcinska A, Britten A. Acceptance testing for nuclear medicine instrumentation. Eur J Nucl Med Mol Imaging. 2010;37:672–81.CrossRefPubMedGoogle Scholar
  12. 12.
    Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431–4.PubMedGoogle Scholar
  13. 13.
    Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.CrossRefPubMedGoogle Scholar
  14. 14.
    Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926–37.CrossRefPubMedGoogle Scholar
  15. 15.
    Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid (6)(8)Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74.CrossRefPubMedGoogle Scholar
  16. 16.
    Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42:1284–94.CrossRefPubMedGoogle Scholar
  17. 17.
    Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. Cancer Imaging. 2016;16:14.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20.CrossRefPubMedGoogle Scholar
  19. 19.
    Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.CrossRefPubMedGoogle Scholar
  20. 20.
    Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients Who have rising PSA after curative treatment and Are being considered for targeted therapy. J Nucl Med. 2015;56:1185–90.CrossRefPubMedGoogle Scholar
  21. 21.
    Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Voo S, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging. 2016;43:397–403.CrossRefPubMedGoogle Scholar
  22. 22.
    Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195:1436–43.CrossRefPubMedGoogle Scholar
  23. 23.
    Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, et al. Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol. 2016;70:553–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography. Prostate. 2015;75:1934–40.CrossRefPubMedGoogle Scholar
  25. 25.
    Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:2114–21.CrossRefPubMedGoogle Scholar
  26. 26.
    Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016;57:1334–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006–13.CrossRefPubMedGoogle Scholar
  28. 28.
    Heck MM, Retz M, D’Alessandria C, Rauscher I, Scheidhauer K, Maurer T, et al. Systemic radioligand therapy with (177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J Urol. 2016;196:382–91.CrossRefPubMedGoogle Scholar
  29. 29.
    Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477–88.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Laidler P, Dulinska J, Lekka M, Lekki J. Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3. Arch Biochem Biophys. 2005;435:1–14.CrossRefPubMedGoogle Scholar
  31. 31.
    Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol. 2014;2:273–85.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer. 2007;14:531–47.CrossRefPubMedGoogle Scholar
  33. 33.
    Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016;70:829–36.CrossRefPubMedGoogle Scholar
  34. 34.
    Giesel FL, Sterzing F, Schlemmer HP, Holland-Letz T, Mier W, Rius M, et al. Intra-individual comparison of Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:1400–6.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Ahmadzadehfar H, Schlenkhoff CD, Rogenhofer S, Yordanova A, Essler M. 68Ga-PSMA-11 PET represents the Tumoricidal effect of 223Ra in a patient with castrate-resistant metastatic prostate cancer. Clin Nucl Med. 2016;41:695–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Donohoe KJ. THE SNM PROCEDURE GUIDELINE FOR GENERAL IMAGING 6.0. 2010. http://snmmi.files.cms-plus.com/docs/General_Imaging_Version_6.0.pdf
  37. 37.
    Murga JD, Moorji SM, Han AQ, Magargal WW, DiPippo VA, Olson WC. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate. 2015;75:242–54.CrossRefPubMedGoogle Scholar
  38. 38.
    Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011;108:9578–82.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Wright Jr GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1:18–28.CrossRefPubMedGoogle Scholar
  40. 40.
    Thomsen H, Webb J. Contrast media safety issues and ESUR guidelines. 3rd ed. Berlin: Springer; 2014.CrossRefGoogle Scholar
  41. 41.
    Media ACoDaC. ACR Manual on Contrast Media, Version 10.2. American College of Radiology 2016.Google Scholar
  42. 42.
    Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and Endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20.CrossRefPubMedGoogle Scholar
  43. 43.
    Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted Theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76.CrossRefPubMedGoogle Scholar
  44. 44.
    Budaus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69:393–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Sawicki LM, Buchbender C, Boos J, Giessing M, Ermert J, Antke C, et al. Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur J Nucl Med Mol Imaging. 2017;44:102–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [(6)(8)Ga]PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging. 2015;42:1622–3.CrossRefPubMedGoogle Scholar
  47. 47.
    Demirci E, Ocak M, Kabasakal L, Decristoforo C, Talat Z, Halac M, et al. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461–2.CrossRefPubMedGoogle Scholar
  48. 48.
    Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5:2674–81.PubMedGoogle Scholar
  49. 49.
    Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–8.PubMedGoogle Scholar
  50. 50.
    Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42:210–4.CrossRefPubMedGoogle Scholar
  51. 51.
    Artigas C, Alexiou J, Garcia C, Wimana Z, Otte FX, Gil T, et al. Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:195–6.CrossRefPubMedGoogle Scholar
  52. 52.
    Hillier SM, Kern AM, Maresca KP, Marquis JC, Eckelman WC, Joyal JL, et al. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med. 2011;52:1087–93.CrossRefPubMedGoogle Scholar
  53. 53.
    Beauregard JM, Hofman MS, Kong G, Hicks RJ. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39:50–6.CrossRefPubMedGoogle Scholar
  54. 54.
    Husband JE, Padhani AR. Radiologists RCo. Recommendations for cross-sectional imaging in cancer management. London: Royal College of Radiologists; 2006.Google Scholar
  55. 55.
    Pfob CH, Ziegler S, Graner FP, Kohner M, Schachoff S, Blechert B, et al. Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC-A PSMA specific probe for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:1962–70.CrossRefPubMedGoogle Scholar
  56. 56.
    Afshar-Oromieh A, Hetzheim H, Kubler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611–20.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Wolfgang P. Fendler
    • 1
    • 2
  • Matthias Eiber
    • 1
    • 3
  • Mohsen Beheshti
    • 4
  • Jamshed Bomanji
    • 5
  • Francesco Ceci
    • 6
  • Steven Cho
    • 7
  • Frederik Giesel
    • 8
  • Uwe Haberkorn
    • 8
  • Thomas A. Hope
    • 9
  • Klaus Kopka
    • 10
  • Bernd J. Krause
    • 11
  • Felix M. Mottaghy
    • 12
    • 13
  • Heiko Schöder
    • 14
  • John Sunderland
    • 15
  • Simon Wan
    • 5
  • Hans-Jürgen Wester
    • 16
  • Stefano Fanti
    • 6
  • Ken Herrmann
    • 1
    • 17
    Email author
  1. 1.Department of Molecular and Medical Pharmacology, David Geffen School of MedicineUCLALos AngelesUSA
  2. 2.Department of Nuclear MedicineLudwig-Maximilians-University of MunichMunichGermany
  3. 3.Department of Nuclear Medicine, Klinikum Rechts der IsarTechnical University of MunichMunichGermany
  4. 4.Department of Nuclear Medicine & Endocrinology, PET-CT CenterSt. Vincent’s HospitalLinzAustria
  5. 5.Institute of Nuclear MedicineUCL/UCLHLondonUK
  6. 6.Nuclear Medicine UnitUniversity of Bologna, S. Orsola Hospital BolognaBolognaItaly
  7. 7.Department of RadiologyUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA
  8. 8.Department of Nuclear MedicineUniversity Hospital Heidelberg and DKFZ HeidelbergHeidelbergGermany
  9. 9.Department of Radiology and Biomedical ImagingUniversity of CaliforniaSan FranciscoUSA
  10. 10.Division of Radiopharmaceutical ChemistryGerman Cancer Research Center (DKFZ) HeidelbergHeidelbergGermany
  11. 11.Department of Nuclear MedicineUniversity Medical Center, University of RostockRostockGermany
  12. 12.Department of Nuclear MedicineUniversity Hospital RWTH Aachen UniversityAachenGermany
  13. 13.Department of Nuclear MedicineMaastricht University Medical Center (MUMC+)MaastrichtThe Netherlands
  14. 14.Memorial Sloan-Kettering Cancer CenterNew YorkUSA
  15. 15.Department of RadiologyUniversity of Iowa Hospitals and ClinicsIowa CityUSA
  16. 16.Pharmaceutical RadiochemistryTechnische Universität MünchenGarchingGermany
  17. 17.Klinik für NuklearmedizinUniversitätsklinikum EssenEssenGermany

Personalised recommendations